The common things for fund are deals in the range of 50 - 100 millions dollars. The higher amount of exits for fund were in 2016. The fund is generally included in less than 2 deals every year. The high activity for fund was in 2018.
Among the most popular portfolio startups of the fund, we may highlight Braeburn, CRISPR Therapeutics. Among the most successful fund investment fields, there are Pharmaceutical, Genetics. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
We also calculated 2 valuable employees in our database.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Wellington Capital Management, startups are often financed by Versant Ventures. The meaningful sponsors for the fund in investment in the same round are New Leaf Venture Partners, Rock Springs Capital, RA Capital Management.
Related Funds
| Fund Name | Location |
| Accelerate Michigan Innovation Competition | Detroit, Michigan, United States |
| AI inside | Japan, Tokyo |
| ASAKASHINKAN GROUP | Asaka, Japan, Saitama Prefecture |
| Avid Technology | Burlington, Massachusetts, United States |
| Beanstalk Ventures | Hartsdale, New York, United States |
| Calvert Social Venture Partners | Bethesda, Maryland, United States |
| Cambridge SamsungPartners | Boston, Massachusetts, United States |
| Dream Project Incubators | Central, Central Region, Singapore |
| EOS technologies | Australia, New South Wales, Pennant Hills |
| Fin Venture Capital | California, San Francisco, United States |
| Freemark holdings | - |
| Gurtin Ventures | Florida, Fort Lauderdale, United States |
| HL Capital | - |
| Hotbed | England, Milton Keynes, United Kingdom |
| JAL Ventures | Herzliya, Israel, Tel Aviv |
| PT Saratoga Investama Sedaya | Indonesia, Jakarta, Jakarta Raya |
| Suffolk Holdings | - |
| Tribe Accelerator | Central, Central Region, Singapore |
| ZGC Group | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
CRISPR Therapeutics | $38M | 24 Jun 2016 | Cambridge, Massachusetts, United States |
– Nuvalent is a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer.
– The company raised $135m in Series B funding.
– Bain Capital Life Sciences led the round and was joined by Deerfield Management, Fidelity Management and Research Company LLC, Wellington Management Company, Viking Global Investors, Janus Henderson Investors, Avoro Capital Advisors, Boxer Capital of Tavistock Group, Venrock Healthcare Capital Partners, Fairmount Funds Management LLC, Driehaus Capital Management LLC, and Logos Capital.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
CRISPR Therapeutics | $38M | 24 Jun 2016 | Cambridge, Massachusetts, United States |
